Cerus shares surge 20.19% after-hours as revenue guidance and strategic growth plans boost investor confidence.

Cerus surged 20.19% in after-hours trading following a strategic update at the TD Cowen Conference and strong earnings performance. The company outlined plans to establish the INTERCEPT Blood System as the global standard, targeting 70% U.S. platelet market share and $224–228 million in 2026 revenue. Recent Q4 2025 results highlighted a 16% revenue increase despite margin pressures, while the earnings report topped estimates with positive EPS revisions. These developments underscore Cerus’s progress in expanding its blood safety technology and achieving growth through strategic agreements, driving investor optimism.